Sox2 function as a negative regulator to control HAMP expression
- Bin Song†1,
- Qi Bian†2,
- Cheng-Hao Shao1,
- An-An Liu1,
- Wei Jing1,
- Rui Liu1,
- Yi-Jie Zhang1,
- Ying-Qi Zhou1,
- Gang Li1Email author and
- Gang Jin1Email author
© Song et al.; licensee BioMed Central. 2015
Received: 21 September 2014
Accepted: 16 April 2015
Published: 6 May 2015
Hepcidin, encoding by HAMP gene, is the pivotal regulator of iron metabolism, controlling the systemic absorption and transportation of irons from intracellular stores. Abnormal levels of HAMP expression alter plasma iron parameters and lead to iron metabolism disorders. Therefore, it is an important goal to understand the mechanisms controlling HAMP gene expression.
Overexpression of Sox2 decrease basal expression of HAMP or induced by IL-6 or BMP-2, whereas, knockdown of Sox2 can increase HAMP expression, furthermore, two potential Sox2-binding sites were identified within the human HAMP promoter. Indeed, luciferase experiments demonstrated that deletion of any Sox2-binding site impaired the negative regulation of Sox2 on HAMP promoter transcriptional activity in basal conditions. ChIP experiments showed that Sox2 could directly bind to these sites. Finally, we verified the role of Sox2 to negatively regulate HAMP expression in human primary hepatocytes.
We found that Sox2 as a novel factor to bind with HAMP promoter to negatively regulate HAMP expression, which may be further implicated as a therapeutic option for the amelioration of HAMP-overexpression-related diseases, including iron deficiency anemia.
KeywordsSox2 Gene expression Hepatocyte HAMP Iron metabolism
Hepcidin, encoding by HAMP gene, is the key regulator of iron homeostasis, and is a small, defensin-like peptide produced by the liver [1,2]. HAMP expression is tightly regulated by many signals including iron content, erythropoietic activity, and inflammation [3-5]. The expression of the HAMP is increased in patients with anemia of chronic disease. Anemia of chronic disease (ACD), also known as anemia of inflammation, is the most prevalent type of anemia in hospitalized patients worldwide [6,7]. The pathogenesis of ACD is characterized by iron-restricted erythropoiesis, whereas iron is retained in the macrophages leading to the disorder of total body iron [8,9]. It has now become clear that inflammatory cytokines released during acute infection or chronic disease can alter systemic iron metabolism by inducing excess synthesis of hepcidin [4,7,8,10]. Treatment of anemia, when necessary, has included administration of iron, packed red cell transfusion, or erythropoiesis-stimulating agents. However, concerns over adverse effects of these therapies, including iron overload, increased risk of infection, recurrence of cancer, and cardiovascular complications, have driven the need for alternative treatments [7,11,12]. Due to the central role of HAMP as described above, inhibition of its biological activity or its expression level may be promising new approaches for the treatment of anemia associated disease.
Sox2 is a member of the Sox family of transcription factors. This protein family shares highly conserved DNA binding domains known as HMG (High-mobility group) box domains containing approximately 80 amino acids . Sox2 is essential for maintaining self-renewal, or pluripotency, of undifferentiated embryonic stem cells [14-16]. We analyzed the HAMP promoter region and putative Sox2 binding sites were identified, suggesting that Sox2 maybe play roles to regulate HAMP expression. In current study, we found that Sox2 functions as the negative regulator to bind with the HAMP promoter to control the HAMP expression. Overexpression of Sox2 in Huh7 cells or HepG2 cells can significantly decrease HAMP expression; in contrast, knockdown Sox2 with siRNA can further increase HAMP expression. We also identified two putative Sox2 binding sites in HAMP promoter and generated the HAMP promoter driven luciferase reporter construct. With this reporter construct, we found that both the Sox2 binding sites are required for Sox2 to exert its negative regulation on HAMP expression; we demonstrated that Sox2 can directly bind with the putative binding sites with ChIP assay. Finally, we also found that Sox2 can downregulate HAMP expression in primary hepatocytes.
In conclusion, our study presents important evidence for the regulation of HAMP expression by Sox2, and this finding can supply a potential therapeutic option to treat anemia of chronic disease.
Results and discussion
Overexpression of Sox2 decrease HAMP expression in hepatoma-derived cells
We searched HAMP expression with BioGPS database (http://biogps.org/) and the analysis suggest that HAMP is highly and specifically expressed in liver tissue (Additional file 1: Figure S1). This result is validated in many cell lines from different tissues with by RT-qPCR assay. As shown in Additional file 1: Figure S2, HAMP is highly expressed in cell lines derived from hepatocytes.
Anemia of chronic disease is a condition caused by increased HAMP production, and is a result of inflammation [7,8]. The central role of HAMP in the maintenance of iron homeostasis suggests that targeting of this peptide may result in therapeutic treatments of iron-overload disorders, so we analyzed the promoter region, aiming to find the transcription factor to control HAMP expression. TFsearch program (http://www.cbrc.jp) and TESS Tool (http://www.cbil.upenn.edu/cgi-bin/tess/tess) analysis suggest that putative Sox2 binding sites were identified in this region, thus, we hypothesize that Sox2 can control the expression of HAMP.
It was reported that IL-6 and BMP-2 could up-regulates transcription of HAMP [5,17]. To further evaluate the inhibitory effect of Sox2 on HAMP expression, we transfected Sox2 into Huh7 cells prior to IL-6 or BMP-2 stimulation, and RT-qPCR assay was performed to determine HAMP expression, as presented in Figure 1B and C, treatment of IL-6 or BMP-2 led to an average of 7.8 or 4.7 folds increase of HAMP, respectively, but this was significantly impaired in Sox2 transfected Huh7 cells, which suggest that Sox2 can inhibit IL-6 or BMP-2 induced HAMP expression (Additional file 1: Figure S4).
Knockdown of Sox2 increase HAMP expression in hepatoma-derived cells
Sox2 regulate HAMP reporter activity
Sox2 can directly bind with HAMP promoter
To further analyze the binding of Sox2 with HAMP promoter, we performed ChIP assay. We transfected Myc-Sox2 into Huh7 cells and then harvested cells at 48 h post-transfection. Cells were processed and the cell lysates were immunoprecipitated with antibodies for Myc or isotype lgG, followed by qPCR using the primer sets (SB primers) specifically for the HAMP promoter sequence to quantify the amount of the HAMP bound DNA, and another primer sets (SB primer(out)) outside of the Sox2 putative binding sites were also used for the qPCR assay for control. As shown in Figure 3D, the amount of HAMP promoter precipitated by Myc increased for about 4-fold as compared to the isotype lgG control. These results revealed direct and specific binding of Sox2 to cis-regulatory sequences in the HAMP promoter region.
Sox2 negatively regulate HAMP expression in primary hepatocytes
HAMP is a small, disulfide-rich peptide produced predominantly by the liver, and plays an important role in regulating systemic iron metabolism in mammals [18,19]. Under physiological conditions, the expression of HAMP is regulated by numerous factors . The known positive regulators are the TfR2 (transferrin receptor 2) [21,22], hereditary HFE (haemochromatosis) protein , BMPs (bone morphogenetic proteins) [17,23,24] and HJV (haemojuvelin) [23-26]. One of negative regulators of liver hepcidin expression is Matriptase-2, a transmembrane serine protease, inhibits the expression of HAMP by interacting with membrane HJV and cleaving it into fragments [27-29]. In previous study, SMAD7 was identified as another negative regulator of HAMP gene expression . SMAD7 is an inhibitory SMAD protein that mediates a negative feedback loop to both TGF-β (transforming growth factor β) and BMP signaling . Sox2 is a member of the SOXB1 subfamily of high-mobility group box proteins and plays a key role in reprogramming somatic cells into pluripotent stem cells and neural stem cells in culture [16,32-35]. Our present study further demonstrates that Sox2 can negatively regulate the expression of HAMP, suggesting that Sox2 might be an important factor to control HAMP expression level to regulate systemic iron metabolism.
In the present study, we found that overexpression of Sox2 can decrease HAMP expression in hepatoma derived cells, and Sox2 can further downregulate IL-6 or BMP-2 induced HAMP expression in these cells (Additional file 1: Figure S4); in contrast, knockdown of Sox2 significantly increase HAMP expression in these cells. All the data support Sox2 as a negative regulator to control HAMP expression. We further constructed HAMP promoter driven reporter system and two putative Sox2 binding sites were identified in the promoter region. We found that the Sox2 binding sites are required for Sox2 to exert its inhibitory effect on the expression of HAMP, and ChIP assay also suggested that Sox2 can directly bind with the HAMP promoter region. Consistent with these results, we showed that the overexpression of Sox2 in human primary hepatocyte cells decreased HAMP expression, whereas knockdown Sox2 can enhance the expression of HAMP. Moreover, the negative regulation of Sox2 on HAMP should be verified in vivo to evaluate its role in the iron metabolism disorder, which is induced by high expression of HAMP. The molecular mechanism of Sox2 regulation of HAMP expression is unknown, and Sox2 has been found to upregulate Rex1 and Nanog with Oct3/4 [36,37]. In this study, we found that Sox2 function as the negative regulator for HAMP expression, which is different from the previous findings. In addition to Oct3/4, Sox2 was found to interact with other molecules, such as Pax6  or NPM1 . The different regulation of Sox2 on the target genes may be dependent on the components of the Sox2 associated complex in the nucleus.
Our discovery shed more light on the transcriptional regulation of HAMP by Sox2 and facilitates understanding the underlying mechanisms of maintaining body iron homeostasis. Interventions targeting this pathway could be useful for therapy of the resulting iron metabolism disorders.
We found that Sox2 as a novel factor to bind with HAMP promoter to negatively regulate HAMP expression, which may be further implicated as a therapeutic option for the amelioration of HAMP-overexpression-related diseases, including iron deficiency anemia.
HEK293 cells, Huh7 cells, A549 cells, BxPC-3 cells, Hela cells, SV-HUC-1 cells, SW1353 cells and RWPE-2 cells, were grown in DMEM medium (Invitrogen, Carlsbad, CA, USA) containing L-glutamine, supplemented with 10% (vol/vol) heat-inactivated fetal calf serum, penicillin (100 units/ml), and streptomycin (100 mg/ml). The human hepatoma HepG2 cells were grown in RPMI 1640 media (Gibco) supplemented with the same components as mentioned above.
To make the Myc-Sox2 expression construct, the cDNA encoding human Sox2 was cloned (nucleotide 438 nt to 1391 nt, GenBank Accession: NM_003106) into pcDNA3-Myc vector; and then the Myc-Sox2 was cloned into pLVX- IRES-Puro lentivirus vector to generate the pLVX-Myc-Sox2-IRES-Puro construct. To construct the HAMP promoter driven luciferase reporter plasmid (HAMP-Luc), a 1,000-bp sequence upstream of the translation start codon was amplified from genomic DNA of Huh7 cells using primers containing KpnI and HindIII sites. The PCR product was then cloned into pGL3-enhancer vector (Promega, Madison, WI, USA) . All the Sox2 binding sites deleted mutants were generated by QuikChange® Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). All constructs were verified by DNA sequencing analysis. The primer information is available upon request.
Plasmid expressing Myc-Sox2, HAMP-Luc or siRNA targeting human Sox2 were transfected into target cells with Lipofectamine™ 2000 (Invitrogen) following manufacture’s instruction.
Lentiviruses expressing the Myc-Sox2 were obtained by co-transfecting pLVX-Myc-Sox2-IRES-Puro with the packaging and envelope vectors into HEK293T cells. Viral supernatants were harvested 48 h post transfection, filtered and used to infect primary hepatocytes.
For western blot analysis, the cells were lysed in sample buffer (20 mM Tris–HCl, pH7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40) containing Complete Protease Inhibitor Cocktail (Roche) and then incubated at 95°C for 10 min. Cell lysates were cleared by centrifugation and supernatants were separated by SDS–PAGE and analyzed by immunoblotting. The Luminata Forte Western HRP Substrate (Millipore) was used for the development of positive signals. The antibodies used in this study include Sox2(Abcam, #ab97959), Myc (Cell Signaling #9402) and beta-Actin (Cell Signaling #4970).
RNA isolation and quantitative RT-PCR
RNA was isolated by TRIzol® Reagent (Life Technologies) in according to the manufacturer’s protocol. RNA pellets were resuspended in diethylpyrocarbonate (DEPC)-treated water and the RNA concentration was determined using the NanoDrop®ND-1000 spectrophotometer (Thermo Scientific). Complementary DNA (cDNA) was synthesized from 1 μg of RNA using random hexmers and TaqMan® Reverse Transcription Reagents (Applied Biosystems, Roche, NJ, USA) and amplified using primers specific for GAPDH (forward: 5′-GAA GGT GAA GGT CGG AGT C-3′; reverse: 5′-GAA GAT GGT GAT GGG ATT TC-3′ . Accession NO.: NM_002046; the length of the amplicon is 226 bp), and HAMP (forward: 5′- CGC TTG CCT CCT GCT CCT-3′; reverse: 5′- CTC GCC TCC TTC GCC TCT-3′. Accession NO.: NM_021175; the length of the amplicon is 152 bp) using SYBR® Green Real time PCR Master Mix (TOYOBO, Osaka, Japan). The specificity is determined by the melt curve analysis. For the data analysis, the Ct (threshold cycle) values for the gene of interested were normalized to those for GAPDH.
Ten thousand Huh7 cells were seeded into 48-well plates overnight prior to transfection with 20 ng/well of HAMP-Luc constructs and 10 ng/well of CMV promoter driven Renilla luciferase vector (pRL-CMV; Promega) together with Myc-Sox2 (0.5ug/well) or not. The cells were harvested 24 h later and cell lysates were assayed for luciferase activities using the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer’s instructions.
Huh7 cells were transfected with Myc-Sox2 and cells were harvested at 48 h posttransfection. Cells were cross-linked, and sonicated to generate chromatin fragments according to a previously described protocol . In particular, the cells were crosslinked with 1% formaldehyde, then lysed and sonicated to shear DNA. Sheared chromatins were then precleaned with protein A agarose. 20% of the sheared chromatins were kept as “input control”. The rest were incubated with antibodies against Myc (Sigma-Aldrich) or normal mouse IgG isotype control followed by additional incubation with protein A agarose. The bead-bound protein-DNA complexes were eluted and crosslinks were reversed. Precipitated DNA was subjected to qPCR using the HAMP promoter primers: 5′-CCA TAT TAC TGC TGT CAT TTA T-3′ and 5′-CAG TGT CAG ACC CTT GAG ATG-3′, and the control primers which were upstream of the Sox2 binding sites as the control: 5′-TTG CCC AGG CTA GTC TTG AA-3′ and 5′-AGC ACA GTG GCT TAT GCC TG-3′. Enrichment values were normalized with corresponding input control.
For siRNA experiments, siRNA targeting human Sox2 (1#: 5′-GGT TGA CAC CGT TGG TAAT-3′; 2#:5′-TGC CGA GAA TCC ATG TATA-3′) was transfected into targeting cells and cells were harvested at indicated time point for further assay. Non-specific oligonucleotides (5-GATCTGATCGACACTGTAATG-3) with no significant homology to any mammalian gene sequence were used as non-silencing controls in all experiments.
Double-stranded oligonucleotides targeting human Sox2 were cloned into the pLSLG lentiviral vector. The sequences targeting human Sox2 are the same with siRNA sequence. HEK293T cells were transfected with the respective lentiviral vectors and packaging vectors to ensure proper viral packaging. Viral supernatants were harvested 48 h post transfection, filtered and used to infect primary hepatocyte cells to knockdown Sox2.
Primary human hepatocytes culture, and lentivirus infection
Human hepatocytes, purchased from PromoCell, were maintained in Hepatocyte Growth Medium (PromoCell, HD, GRE). Cells were plated at a density of 1 × 105 cells on 48-well plates coated with type 1 collagen. The produced lentiviruses for Myc-Sox2 transduction and Sox2 shRNA knockdown mentioned aboved were inoculated to primary human hepatocytes. Three days later the lentivirus-transduced cells were collected for RT-qPCR analysis of HAMP expression.
Statistical analysis of the data was performed by using the GraphPad Prism software (GraphPad Software). Specific tests are noted in figure legends.
We would like to express our appreciation to Drs. Wen Wen and Guang-Hua Rong for their constructive supervision and discussion. This project was supported by Shanghai Municipal Natural Science Foundation (Grant No. 12ZR1453900).
- Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–8. doi:10.1182/blood-2003-03-0672.View ArticlePubMedGoogle Scholar
- Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3. doi:10.1126/science.1104742.View ArticlePubMedGoogle Scholar
- Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–33. doi:10.1182/blood-2011-01-258467.View ArticlePubMed CentralPubMedGoogle Scholar
- Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–6. doi:10.1172/JCI20945.View ArticlePubMed CentralPubMedGoogle Scholar
- Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A. 2004;101(25):9263–5. doi:10.1073/pnas.0403108101.View ArticlePubMed CentralPubMedGoogle Scholar
- Lawen A, Lane DJ. Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid Redox Signal. 2013;18(18):2473–507. doi:10.1089/ars.2011.4271.View ArticlePubMedGoogle Scholar
- Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–23. doi:10.1056/NEJMra041809.View ArticlePubMedGoogle Scholar
- Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113(9):1251–3. doi:10.1172/JCI21441.View ArticlePubMed CentralPubMedGoogle Scholar
- Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117(3):285–97.View ArticlePubMedGoogle Scholar
- Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811–9. doi:10.1074/jbc.M008923200.View ArticlePubMedGoogle Scholar
- Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55. doi:10.1056/NEJMoa1005109.View ArticlePubMedGoogle Scholar
- Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–59. doi:10.1182/blood-2010-08-300541.View ArticlePubMedGoogle Scholar
- Wiebe MS, Nowling TK, Rizzino A. Identification of novel domains within Sox-2 and Sox-11 involved in autoinhibition of DNA binding and partnership specificity. J Biol Chem. 2003;278(20):17901–11. doi:10.1074/jbc.M212211200.View ArticlePubMedGoogle Scholar
- Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell stem cell. 2013;12(1):15–30. doi:10.1016/j.stem.2012.12.007.View ArticlePubMed CentralPubMedGoogle Scholar
- Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 2007;9(6):625–35. doi:10.1038/ncb1589.View ArticlePubMedGoogle Scholar
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76. doi:10.1016/j.cell.2006.07.024.View ArticlePubMedGoogle Scholar
- Matak P, Chaston TB, Chung B, Srai SK, McKie AT, Sharp PA. Activated macrophages induce hepcidin expression in HuH7 hepatoma cells. Haematologica. 2009;94(6):773–80. doi:10.3324/haematol.2008.003400.View ArticlePubMed CentralPubMedGoogle Scholar
- Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–10. doi:10.1074/jbc.M008922200.View ArticlePubMedGoogle Scholar
- De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol. 2008;9(1):72–81. doi:10.1038/nrm2295.View ArticlePubMedGoogle Scholar
- Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2009:207-14. doi:10.1182/asheducation-2009.1.207.
- Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006;281(39):28494–8. doi:10.1074/jbc.C600197200.View ArticlePubMedGoogle Scholar
- Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O'Kelly J, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005;105(1):376–81. doi:10.1182/blood-2004-04-1416.View ArticlePubMedGoogle Scholar
- Zhang AS, Gao J, Koeberl DD, Enns CA. The role of hepatocyte hemojuvelin in the regulation of bone morphogenic protein-6 and hepcidin expression in vivo. J Biol Chem. 2010;285(22):16416–23. doi:10.1074/jbc.M110.109488.View ArticlePubMed CentralPubMedGoogle Scholar
- Zhang AS, Yang F, Wang J, Tsukamoto H, Enns CA. Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. J Biol Chem. 2009;284(34):22580–9. doi:10.1074/jbc.M109.027318.View ArticlePubMed CentralPubMedGoogle Scholar
- Zhang AS. Control of systemic iron homeostasis by the hemojuvelin-hepcidin axis. Adv Nutr. 2010;1(1):38–45. doi:10.3945/an.110.1009.View ArticlePubMed CentralPubMedGoogle Scholar
- Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007;282(17):12547–56. doi:10.1074/jbc.M608788200.View ArticlePubMedGoogle Scholar
- Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088–92. doi:10.1126/science.1157121.View ArticlePubMed CentralPubMedGoogle Scholar
- Folgueras AR, de Lara FM, Pendas AM, Garabaya C, Rodriguez F, Astudillo A, et al. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood. 2008;112(6):2539–45. doi:10.1182/blood-2008-04-149773.View ArticlePubMedGoogle Scholar
- Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell metabolism. 2008;8(6):502–11. doi:10.1016/j.cmet.2008.09.012.View ArticlePubMed CentralPubMedGoogle Scholar
- Mleczko-Sanecka K, Casanovas G, Ragab A, Breitkopf K, Muller A, Boutros M, et al. SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood. 2010;115(13):2657–65. doi:10.1182/blood-2009-09-238105.View ArticlePubMedGoogle Scholar
- Patel N, Masaratana P, Diaz-Castro J, Latunde-Dada GO, Qureshi A, Lockyer P, et al. BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotransferrinemic mice. J Biol Chem. 2012;287(6):4099–106. doi:10.1074/jbc.M111.310789.View ArticlePubMed CentralPubMedGoogle Scholar
- Ring KL, Tong LM, Balestra ME, Javier R, Andrews-Zwilling Y, Li G, et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell stem cell. 2012;11(1):100–9. doi:10.1016/j.stem.2012.05.018.View ArticlePubMed CentralPubMedGoogle Scholar
- Lujan E, Chanda S, Ahlenius H, Sudhof TC, Wernig M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci U S A. 2012;109(7):2527–32. doi:10.1073/pnas.1121003109.View ArticlePubMed CentralPubMedGoogle Scholar
- Han DW, Tapia N, Hermann A, Hemmer K, Hoing S, Arauzo-Bravo MJ, et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell stem cell. 2012;10(4):465–72. doi:10.1016/j.stem.2012.02.021.View ArticlePubMedGoogle Scholar
- Kim J, Efe JA, Zhu S, Talantova M, Yuan X, Wang S, et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci U S A. 2011;108(19):7838–43. doi:10.1073/pnas.1103113108.View ArticlePubMed CentralPubMedGoogle Scholar
- Shi W, Wang H, Pan G, Geng Y, Guo Y, Pei D. Regulation of the pluripotency marker Rex-1 by Nanog and Sox2. J Biol Chem. 2006;281(33):23319–25. doi:10.1074/jbc.M601811200.View ArticlePubMedGoogle Scholar
- Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2005;280(26):24731–7. doi:10.1074/jbc.M502573200.View ArticlePubMedGoogle Scholar
- Aota S, Nakajima N, Sakamoto R, Watanabe S, Ibaraki N, Okazaki K. Pax6 autoregulation mediated by direct interaction of Pax6 protein with the head surface ectoderm-specific enhancer of the mouse Pax6 gene. Dev Biol. 2003;257(1):1–13.View ArticlePubMedGoogle Scholar
- Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009;460(7251):118–22. doi:10.1038/nature08113.View ArticlePubMedGoogle Scholar
- Doyle SL, Shirey KA, McGettrick AF, Kenny EF, Carpenter S, Caffrey BE, et al. Nuclear factor kappaB2 p52 protein has a role in antiviral immunity through IkappaB kinase epsilon-dependent induction of Sp1 protein and interleukin 15. J Biol Chem. 2013;288(35):25066–75. doi:10.1074/jbc.M113.469122.View ArticlePubMed CentralPubMedGoogle Scholar
- Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14(18):2314–29.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.